More specifically, MI-888 seems to be a potent inhibitor of MDM2–p53 interaction, capable of achieving complete regression of two types of human cancers through oral administration, such as SJSA-1 osteosarcoma and RS4;11 acute lymphoblastic leukaemia tumour xenograft models. Here, MDM2 is linked to cancer.